18th Sep 2009 09:08
For release: 18 September 2009
Epistem Plc
Notice of Preliminary Results
Epistem Plc (AIM: EHP), the rapidly growing biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases will announce its Preliminary Results for the year ended 30th June 2009 on the 6th October 2009.
The results presentation will be held at the offices of Piper Jaffray at One South Place, London, EC2M 2RB at 9.30am on the day. If you would like to attend, please contact the team at De Facto Communications below.
For further details please contact:
Epistem
Matthew Walls
Chief Executive Officer +44 (0)161 606 7258
John Rylands
Finance Director
Piper Jaffray
Neil Mackison / Rupert Winckler +44 (0) 20 3142 8700
De Facto Communications
Mike Wort / Anna Dunphy +44 (0) 20 7681 3838
Notes to Editors
Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.
Related Shares:
Genedrive